Main page content

Displaying results 1 - 6 of 6
Publication ID: PEP21-02-01-003
Published:

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

Publication ID: PEP21-02-01-002
Published:

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

Publication ID: SMA16-4952SPANISH
Published:
This fact sheet recognizes wellness as an important part of recovery and notes its value in reducing morbidity and mortality among people living with mental illness. It explains the eight dimensions of wellness and how these dimensions impact overall health.
Publication ID: SMA16-4952
Published:

This fact sheet recognizes wellness as an important part of recovery and notes its value in reducing morbidity and mortality among people living with mental illness. It explains the eight dimensions of wellness and how these dimensions impact overall health.

Publication ID: SMA13-4153
Published:

This comprehensive kit provides substance use disorder treatment professionals with a year-long intensive outpatient treatment model. Professionals can use this model when treating clients who are dependent on stimulant drugs, such as methamphetamine and cocaine.

The referenced PowerPoint Presentation Sessions are available for download.

View recommendations for related products.

Publication ID: SMA13-4773
Published:

This handbook reviews Medicaid and its role in financing services and treatment for mental illness and substance use disorders. It discusses services included in state Medicaid plans and other factors related to Medicaid, such as reimbursement.